Netherlands· NL-279899658e1a
Vabysmo 120 mg/ml, oplossing voor injectie
A faricimab product containing faricimab, registered in Netherlands by Roche Registration GmbH. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Faricimab is registered in 14 of 19 countries.
Countries holding a registration under ATC S01LA09 (faricimab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Faricimab · ATC S01LA09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- FARICIMAB
- Manufacturer
- Roche Registration GmbH
- Country
- Netherlands (NL)
- ATC code
- S01LA09
- ATC class
- Faricimab
- Defined daily dose
- 0.0357 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/22/1683
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Faricimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainVABYSMO 120 MG/ML SOLUCION INYECTABLERoche Registration Gmbh
- SwitzerlandVabysmo 6 mg/0,05 ml, InjektionslösungRoche Pharma (Schweiz) AG
- CzechiaVABYSMORoche Registration GmbH, Grenzach-Wyhlen
- SwedenVABYSMO 120 mg/ml Injektionsvätska, lösningRoche Registration GmbH
- NorwayVabysmoRoche Registration GmbH
- BelgiumVabysmo 120 mg/mlRoche Registration
- IrelandVabysmo 120 mg/mL solution for injectionRoche Registration GmbH
- IcelandVabysmoRoche Registration GmbH*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vabysmo
- Liechtenstein · Vabysmo
- Norway · Vabysmo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e531035d-a392-4f80-9fea-d25e244f2f87 GET /v1/drugs/e531035d-a392-4f80-9fea-d25e244f2f87?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Intravitreaal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Faricimab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128478",
"excipients": [
"AZIJNZUUR (E 260)",
"HISTIDINE, (L-)",
"METHIONINE, (L-)",
"NATRIUMCHLORIDE",
"POLYSORBAAT 20 (E 432)",
"SACCHAROSE",
"WATER VOOR INJECTIE"
],
"substances": [
"FARICIMAB"
],
"leaflet_url": null,
"authorised_at": "2022/09/15",
"procedure_number": "EMEA/H/C/005642",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/22/1683",
"additional_monitoring": "N"
}See everything about faricimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.